Loading
Life sciences · Journal article
Bioactive Materials · September 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Osteoarthritis (OA) is a whole-joint disease characterized by progressive structural degeneration and chronic low-grade inflammation affecting the cartilage, synovium, subchondral bone, and immune compartments. It is a complex degenerative disorder associated with substantial morbidity, heterogeneous clinical trajectories, and limited disease-modifying treatment options. Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication within the OA joint microenvironment, and are implicated in pathophysiological responses to mechanical stress, inflammatory cues, and metabolic dysfunction. Through the transfer of context-dependent nucleic acid, protein, and lipid cargoes, EVs can amplify pathogenic processes in OA such as synovitis, cartilage catabolism, and cellular senescence, while also supporting reparative pathways. Understanding the mechanisms governing EV biogenesis, cargo selection, tissue targeting, and functional heterogeneity offers opportunities to identify mechanistically informed biomarkers and therapeutic strategies. This review discusses emerging concepts in EV-mediated joint communication, highlights translational potential and limitations, and outlines key priorities for advancing EV-based diagnostics and therapies in OA. However, EV-based strategies remain largely at the preclinical or experimental stage, and rigorous validation is required before they can enter routine clinical practice.